Brain ACE2 in Alzheimer's disease in relation to COVID-19

Information

  • Research Project
  • 10295482
  • ApplicationId
    10295482
  • Core Project Number
    R21AG073919
  • Full Project Number
    1R21AG073919-01
  • Serial Number
    073919
  • FOA Number
    PAR-18-836
  • Sub Project Id
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    HSIAO, JOHN
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/31/2021 - 2 years ago
Organizations

Brain ACE2 in Alzheimer's disease in relation to COVID-19

Summary/Abstract Currently the world is suffering from the pandemics of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter host cells. Millions of people have been infected with SARS-CoV- 2 and over 1 million people have died of COVID-19 worldwide, causing serious health, economical, and sociological problems. In Ukraine, a low- and middle-income country (LMICs) with a population of 42 million, 400,000 cases have been confirmed with 7,000 deaths. The aging population is highly susceptible to be severely affected by and die of COVID-19. Neurological manifestations have been reported to occur in a large number of COVID-19 patients, suggesting that this disease may also exert the long-term adverse neurological consequences. However, the effects of SARS-CoV-2 on human host cells, particularly those in the brain, have not been defined. Lack of such knowledge interferes with the development of therapeutic strategies to combat COVID-19. The long-term objective of our research is to define the relationships between neurological disorders and COVID-19. We recently found that Alzheimer's disease patients have the upregulated hippocampal ACE2 expression. In this international collaborative exploratory/pilot Fogarty project, we will test the central hypothesis that the oxidative stress in Alzheimer's disease promotes cell signaling and gene expression mechanisms to upregulate ACE2 that in turn increases the infection by SARS-CoV-2 in the brains of these patients. This project will also engage in research capacity building for Ukraine. We plan to accomplish the objective by addressing the following specific aims: (1) Engage in research capacity building for Ukraine, one of low- and middle-income countries; (2) Define the mechanism of ACE2 gene expression in Alzheimer's brain; and (3) Identify the role of brain ACE2 in Alzheimer's disease in relation to COVID-19. This project is innovative because it will address a novel pathology of COVID-19. Results of this project are significant because they are expected to contribute to the development of new therapeutic agents to reduce the mortality and morbidity caused by COVID-19 that occurs largely in the aging population while building the research capacity in Ukraine. .

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R21
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
    130200
  • Indirect Cost Amount
    47600
  • Total Cost
    177800
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    FIC:5000\NIA:172800\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GEORGETOWN UNIVERSITY
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    049515844
  • Organization City
    WASHINGTON
  • Organization State
    DC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    200570001
  • Organization District
    UNITED STATES